A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer

Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the prostate * Metastatic disease progressing despite castrate levels of testosterone * Prostate cancer progression documented by PSA * Surgically or medically castrated, with testosterone levels of \< 50 ng/dL * Previous anti-androgen therapy and progression after withdrawal * ECOG performance status of 0 to 1 * Adequate organ function * Prior radiation therapy allowed to \< 25% of the bone marrow * Prior hormonal therapy is allowed * Patient compliance and geographic proximity that allow adequate follow-up. * Patients with reproductive potential must use contraceptive methods * Signed informed consent from patient Exclusion Criteria: * Active infection * Any chronic medical condition requiring a high doses of corticosteroid * Pathological finding consistent with small cell carcinoma of the prostate * Brain metastasis * Prior cytotoxic chemotherapy or biologic therapy for the treatment of CRPC * Radiation therapy for treatment of the primary tumor within 6 weeks * Radionuclide therapy for treatment of metastatic CRPC * Prior systemic treatment with an azole drug * Prior flutamide treatment within 4 weeks * Prior bicalutamide or nilutamide within 6 weeks * Congenital long QT syndrome, congestive heart failure, or bradyarrhythmia * Administration of an investigational therapeutic within 2 weeks * Second primary malignancy * Presence of clinically detectable third-space fluid collections * History of severe hypersensitivity reaction to polysorbate 80 * Peripheral neuropathy at study entry